<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771342</url>
  </required_header>
  <id_info>
    <org_study_id>CTP 6</org_study_id>
    <nct_id>NCT00771342</nct_id>
  </id_info>
  <brief_title>Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)</brief_title>
  <official_title>A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the fungicidal efficacy of nitric oxide and it's
      effect on the clinical signs and symptoms associated with Tinea Pedis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of fungicidal activity as confirmed by mycological culture or microscopic evaluation and improvement in Clinical Symptom Severity Score</measure>
    <time_frame>Day 12 or Day 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tinea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrogen</intervention_name>
    <description>Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive clinical findings for moccasin, interdigital or bullous tinea pedis as
             determined by direct clinical examination

          -  Must have a clinical symptom severity score of at least 20 on a possible 64 point
             scale

          -  Written informed consent must be obtained from the subject.

          -  Must ≥ 19 years of age

          -  Must agree to avoid professional pedicures or application of any nail polish product
             or nail cosmetic to the toenails after the screening visit until the conclusion of the
             trial.

          -  Must agree to take measures to avoid pregnancy during the 12 day (or 26 day if in
             cross over group) study period

        Exclusion Criteria:

          -  Has a diagnosis of either psoriasis or eczema

          -  Has a visual diagnosis, by the investigator, of onychomycosis.

          -  Use of topical antifungals e.g. (clotrimazole, ketoconazole,miconazole, oxiconazole-
             (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole,
             econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, ciclopirox
             olamine-(Loprox®, Medicis), tolnaftate, haloprogin), Zeasorb-AF , antibacterials and
             corticosteroids in the preceding 5 days of screening visit (Day 1)

          -  Use of systemic corticosteroids in the preceding 7 days of screening visit (Day 1)

          -  Use of systemic antifungals in the preceding 7 days of screening visit (Day1)
             including - (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen),
             fluconazole- (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (Gris-PEG®,
             Pedinol), butoconazole, terconazole, Potassium iodide)

          -  Has used any investigational drug(s) within 30 days preceding screening visit (Day 1)

          -  Has cardiovascular disease, diabetes mellitus, Cushing's Disease, hematological
             malignancy, chronic mucocutaneous candidiasis or atopy

          -  Is pregnant or is a nursing mother

          -  Is a woman of child bearing potential who is not using an adequate form of
             contraception (or abstinence)

          -  Is &lt; 19 years of age

          -  Suffers from a condition, which, in the opinion of the medical investigator, would
             compromise his/her safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>February 2, 2010</last_update_submitted>
  <last_update_submitted_qc>February 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Technology Officer</name_title>
    <organization>Nitric BioTherapeutics, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

